Clinical Trials Logo
  1. Home
  2. Lymphoma, T-Cell, Peripheral
  3. NCT03547700

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Lymphoma, T-Cell, Peripheral Clinical Trial

Official title:
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)

Clinical Trial Summary

Single arm phase I/II study of ixazomib and romidepsin in relapsed/refractory PTCL. Each cycle is 28 days. Patients will continue to receive therapy until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met. The phase I study includes three dose levels. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03547700
Study type Interventional
Source Big Ten Cancer Research Consortium
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date September 26, 2018
Completion date July 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT02788916 - A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas N/A
Completed NCT02567656 - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Phase 1
Completed NCT01142674 - T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
Withdrawn NCT03355768 - Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Phase 3
Not yet recruiting NCT05006664 - Brentuximab Vedotin in Combination With CHEP in Patient With PTCL Phase 2
Terminated NCT00514722 - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies N/A
Completed NCT01679860 - Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma Phase 2
Recruiting NCT06254495 - A Safety Study of SGN-35C in Adults With Advanced Cancers Phase 1
Completed NCT05137847 - A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Terminated NCT03601819 - Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Phase 1
Completed NCT03049449 - T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Phase 1
Completed NCT00211185 - A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Phase 2
Not yet recruiting NCT03051581 - 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma N/A
Not yet recruiting NCT03051568 - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma N/A
Completed NCT00646854 - Alemtuzumab and CHOP in T-cell Lymphoma Phase 3
Terminated NCT02535247 - Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT02364466 - Cohort of Peripheral T Cell Lymphoma N/A
Recruiting NCT02404571 - GDP in Frontline Chemotherapy for Patients With PTCL-NOS Phase 2
Completed NCT03742921 - ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
Completed NCT02181218 - Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Phase 1